Drug General Information
Drug ID	D0Q4GJ
Former ID	DNC004776
Drug Name	2-Pyridin-3-yl-benzo[h]chromen-4-one
Drug Type	Small molecular drug
Indication	Discovery agent		Investigative	[527386]
Structure		Download 2D MOL 3D MOL
Formula	C18H11NO2
Canonical SMILES	C1=CC=C2C(=C1)C=CC3=C2OC(=CC3=O)C4=CN=CC=C4
InChI	1S/C18H11NO2/c20-16-10-17(13-5-3-9-19-11-13)21-18-14-6-2-1-4-12(14)7-8-15(16)18/h1-11H
InChIKey	RURRJHXFMININK-UHFFFAOYSA-N
PubChem Compound ID	323484
Target and Pathway
Target(s)	DNA-dependent protein kinase catalytic subunit	Target Info	Inhibitor	[527386]
KEGG Pathway	Non-homologous end-joining
	Cell cycle
NetPath Pathway	IL1 Signaling Pathway
Pathway Interaction Database	DNA-PK pathway in nonhomologous end joining
	Coregulation of Androgen receptor activity
	Class I PI3K signaling events mediated by Akt
	BARD1 signaling events
Reactome	Nonhomologous End-Joining (NHEJ)
WikiPathways	DNA Damage Response
	Non-homologous end joining
	FAS pathway and Stress induction of HSP regulation
	Cytosolic sensors of pathogen-associated DNA
	Retinoblastoma (RB) in Cancer
	Prostate Cancer
	Double-Strand Break Repair
	Cell Cycle
	miRNA Regulation of DNA Damage Response
References
Ref 527386	J Med Chem. 2005 Jan 27;48(2):569-85.Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and radiosensitization of a human tumor cell line in vitro.
Ref 527386	J Med Chem. 2005 Jan 27;48(2):569-85.Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and radiosensitization of a human tumor cell line in vitro.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.